Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis : A 48-week prospective single-center study
BACKGROUND: Serum neurofilament light (sNfL) reflects neuroaxonal damage and is now used as an outcome in treatment trials of relapsing-remitting multiple sclerosis (RRMS). However, the diagnostic properties of sNfL for monitoring disease activity in individual patients warrant further investigations.
METHOD: Patients with suspected relapse and/or contrast-enhancing lesions (CELs) were consecutively included and performed magnetic resonance imaging (MRI) of the brain at baseline and weeks 28 and 48. Serum was obtained at baseline and 2, 4, 8, 16, 24, and 48 weeks. Neurofilament light concentration was measured using Single molecule array technology.
RESULTS: We included 44 patients, 40 with RRMS and 4 with clinically isolated syndrome. The median sNfL level peaked at 2 weeks post-baseline (14.6 ng/L, interquartile range (IQR); 9.3-31.6) and reached nadir at 48 weeks (9.1 ng/L, IQR; 5.5-15.0), equivalent to the median sNfL of controls (9.1 ng/L, IQR; 7.4-12). A baseline Z-score of more than 1.1 (area under the curve; 0.78, p < 0.0001) had a sensitivity of 81% and specificity of 70% to detect disease activity.
CONCLUSION: One out of five patients with relapse and/or CELs did not change significantly in post-baseline sNfL levels. The utility of repeated sNfL measurements to monitor disease activity is complementary rather than a substitute for clinical and MRI measures.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Multiple sclerosis (Houndmills, Basingstoke, England) - (2024) vom: 13. März, Seite 13524585241237388 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Johnsson, M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Revised 14.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1177/13524585241237388 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369707796 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369707796 | ||
| 003 | DE-627 | ||
| 005 | 20240315000423.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/13524585241237388 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1329.xml |
| 035 | |a (DE-627)NLM369707796 | ||
| 035 | |a (NLM)38481083 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Johnsson, M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis |b A 48-week prospective single-center study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 14.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a BACKGROUND: Serum neurofilament light (sNfL) reflects neuroaxonal damage and is now used as an outcome in treatment trials of relapsing-remitting multiple sclerosis (RRMS). However, the diagnostic properties of sNfL for monitoring disease activity in individual patients warrant further investigations | ||
| 520 | |a METHOD: Patients with suspected relapse and/or contrast-enhancing lesions (CELs) were consecutively included and performed magnetic resonance imaging (MRI) of the brain at baseline and weeks 28 and 48. Serum was obtained at baseline and 2, 4, 8, 16, 24, and 48 weeks. Neurofilament light concentration was measured using Single molecule array technology | ||
| 520 | |a RESULTS: We included 44 patients, 40 with RRMS and 4 with clinically isolated syndrome. The median sNfL level peaked at 2 weeks post-baseline (14.6 ng/L, interquartile range (IQR); 9.3-31.6) and reached nadir at 48 weeks (9.1 ng/L, IQR; 5.5-15.0), equivalent to the median sNfL of controls (9.1 ng/L, IQR; 7.4-12). A baseline Z-score of more than 1.1 (area under the curve; 0.78, p < 0.0001) had a sensitivity of 81% and specificity of 70% to detect disease activity | ||
| 520 | |a CONCLUSION: One out of five patients with relapse and/or CELs did not change significantly in post-baseline sNfL levels. The utility of repeated sNfL measurements to monitor disease activity is complementary rather than a substitute for clinical and MRI measures | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multiple sclerosis | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a disease activity | |
| 650 | 4 | |a neurofilament light | |
| 650 | 4 | |a prospective study | |
| 700 | 1 | |a Stenberg, Y T |e verfasserin |4 aut | |
| 700 | 1 | |a Farman, H H |e verfasserin |4 aut | |
| 700 | 1 | |a Blennow, K |e verfasserin |4 aut | |
| 700 | 1 | |a Zetterberg, H |e verfasserin |4 aut | |
| 700 | 1 | |a Malmeström, C |e verfasserin |4 aut | |
| 700 | 1 | |a Sandgren, S |e verfasserin |4 aut | |
| 700 | 1 | |a Rosenstein, I |e verfasserin |4 aut | |
| 700 | 1 | |a Lycke, J |e verfasserin |4 aut | |
| 700 | 1 | |a Axelsson, M |e verfasserin |4 aut | |
| 700 | 1 | |a Novakova, L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Multiple sclerosis (Houndmills, Basingstoke, England) |d 1997 |g (2024) vom: 13. März, Seite 13524585241237388 |w (DE-627)NLM09012992X |x 1477-0970 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:13 |g month:03 |g pages:13524585241237388 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/13524585241237388 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 13 |c 03 |h 13524585241237388 | ||